Anika Therapeutics (ANIK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 30,615 | 27,817 | 28,219 | 26,168 | 30,602 |
| Cost of Goods | 11,436 | 12,233 | 13,856 | 11,487 | 13,476 |
| Gross Profit | 19,179 | 15,584 | 14,363 | 14,681 | 17,126 |
| Operating Expenses | 18,969 | 19,050 | 19,399 | 19,452 | 18,307 |
| Operating Income | 646 | -3,233 | -4,180 | -4,284 | -705 |
| Other Income | 118 | 997 | 214 | 415 | 744 |
| Pre-tax Income | 764 | -2,236 | -3,966 | -3,869 | 39 |
| Income Tax | -1,037 | 939 | 681 | 89 | 2,525 |
| Net Income Continuous | 1,801 | -3,175 | -4,647 | -3,958 | -2,486 |
| Net Income Discontinuous | -1,509 | 846 | 677 | -915 | -19,379 |
| Net Income | $292 | $-2,329 | $-3,970 | $-4,873 | $-21,865 |
| EPS Basic Total Ops | 0.02 | -0.16 | -0.28 | -0.34 | -1.48 |
| EPS Basic Continuous Ops | 0.13 | -0.22 | -0.33 | -0.28 | -0.18 |
| EPS Basic Discontinuous Ops | -0.11 | 0.06 | 0.05 | -0.06 | -1.30 |
| EPS Diluted Total Ops | 0.02 | -0.16 | -0.28 | -0.34 | -1.48 |
| EPS Diluted Continuous Ops | 0.13 | -0.22 | -0.33 | -0.28 | -0.18 |
| EPS Diluted Discontinuous Ops | -0.11 | 0.06 | 0.05 | -0.06 | -1.31 |
| EPS Diluted Before Non-Recurring Items | 0.13 | -0.17 | -0.33 | -0.28 | -0.14 |
| EBITDA(a) | $1,964 | $-1,830 | $-2,764 | $-2,692 | $468 |